Kestra Medical Technologies Ltd (NASDAQ: KMTS) is a medical device company that develops and commercializes a wearable cardioverter defibrillator system for patients at elevated risk of sudden cardiac arrest. Revenue comes from leasing its ASSURE Wearable Cardioverter Defibrillator to patients, with reimbursement flowing primarily from Medicare, Medicaid, and private payors. The ASSURE WCD anchors the Cardiac Recovery System platform, which integrates cardiac monitoring, therapeutic defibrillation, digital health tools, and patient support services into a single system. Kestra completed its IPO on March 7, 2025, issuing 13,664,704 common shares at $17.00 per share for net proceeds of $215.8 million. As of April 30, 2025, the U.S. commercial team included approximately 80 direct sales representatives, more than 40 sales and clinical support professionals, and over 300 contracted patient support specialists. Brian Webster, a company founder, has served as President and CEO since 2014. The company is headquartered in the U.S. medical device sector and operates a device-leasing model in which each unit supports approximately three patient wears per year after reprocessing.

Revenue model

Lease-based model: the ASSURE WCD is prescribed to patients and leased rather than sold outright. Revenue realization depends on reimbursement from Medicare, Medicaid, and private payors. Gross profit is affected by wear duration, payor mix, and reimbursement rates.

Products and services

ASSURE Wearable Cardioverter Defibrillator (ASSURE WCD): a garment-based device integrating four-channel ECG monitoring, defibrillation therapy, mobile connectivity, and performance fabric construction. The broader Cardiac Recovery System platform adds digital health monitoring and patient support services. Each device is reprocessed after patient use and supports approximately three patient wears per year (per 10-K filed 2025-07-17).

Customers and end markets

Patients with elevated risk of sudden cardiac arrest, prescribed by cardiologists and electrophysiologists. Healthcare providers, including those treating newly diagnosed heart failure patients receiving guideline-directed medical therapy, are the prescribing channel. Third-party payors, principally Medicare, Medicaid, and private insurers, are the primary payers.

Value-chain role

Kestra designs, manufactures, distributes, and reprocesses the ASSURE WCD. It operates its own direct sales and clinical support team, a contracted patient-fitting network of over 300 specialists (as of April 30, 2025), and an in-house revenue cycle management function to handle payor reimbursement. Device reprocessing and redistribution are handled through Kestra's own distribution network.

Geographic exposure

U.S. commercial operations are the disclosed focus. No international revenue or operations are described in the filing excerpts.

Source: SEC 10-K, filed 2025-07-17

Industry: Surgical & Medical Instruments & Apparatus